Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hangzhou Cancerprobe Biological Technology Co. Ltd. has 1 pending office action in the Chemistry & Materials technology area. This action is assigned to 1 distinct examiner, Robert J Eom, reflecting a targeted approach to its current chemistry and materials patent applications. Since there is only 1 pending office action, the entire active portfolio is concentrated with this one examiner. This suggests a highly specific technical focus for the company's current research and development efforts.
Robert J Eom is the busiest examiner for the company, managing 1 busiest examiner pending action. The portfolio is limited to 1 distinct art unit. This concentration in 1 distinct art unit suggests that the subject matter is highly specialized within the chemistry field. For practitioners, the alignment of the 1 pending office action with a single examiner and art unit means that the prosecution strategy is entirely dependent on the specific requirements of Robert J Eom. This singular focus allows for a deep and consistent technical dialogue during the examination process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EOM, ROBERT J | 1 | 57.4% | +34.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18315213 | Method for diagnosing breast cancer by using biomarker | EOM, ROBERT J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18315213 | Method for diagnosing breast cancer by using biomarker | EOM, ROBERT J | — |
| Art Unit | Apps |
|---|---|
| 1797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18315213 | Method for diagnosing breast cancer by using biomarker | EOM, ROBERT J | 1797 | §102§103§112 | Non-Final OA | — | Pending | May 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHangzhou Cancerprobe Biological Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert J Eom has the most, with 1 of Hangzhou Cancerprobe Biological Technology Co. Ltd.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
